

Joslyn Kirby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5621870/publications.pdf>

Version: 2024-02-01

71
papers

2,122
citations

331670

21
h-index

254184

43
g-index

72
all docs

72
docs citations

72
times ranked

1463
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. <i>JAMA Dermatology</i> , 2017, 153, 760.	4.1	258
2	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 76-90.	1.2	218
3	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 91-101.	1.2	206
4	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 366-376.	1.2	165
5	A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. <i>British Journal of Dermatology</i> , 2018, 179, 642-650.	1.5	119
6	What causes hidradenitis suppurativa? 15 years after. <i>Experimental Dermatology</i> , 2020, 29, 1154-1170.	2.9	90
7	Intralesional chemotherapy for nonmelanoma skin cancer: A practical review. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 689-702.	1.2	87
8	Health Care Utilization Patterns and Costs for Patients With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2014, 150, 937.	4.1	87
9	Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa. <i>JAMA Surgery</i> , 2021, 156, 1001.	4.3	62
10	Association of Resilience With Depression and Health-Related Quality of Life for Patients With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2017, 153, 1263.	4.1	59
11	The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. <i>British Journal of Dermatology</i> , 2020, 183, 340-348.	1.5	52
12	Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 609-614.	1.2	46
13	Janus kinase 1 inhibitor INC054707 for patients with moderate to severe hidradenitis suppurativa: results from two phase II studies*. <i>British Journal of Dermatology</i> , 2022, 186, 803-813.	1.5	44
14	A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: Investigating practice gaps and potential cost-savings. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 70-76.	1.2	43
15	Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. <i>BMJ Open</i> , 2017, 7, e014733.	1.9	37
16	Development of a Quality-of-Life Measure for Hidradenitis Suppurativa. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 152-155.	1.2	35
17	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. <i>British Journal of Dermatology</i> , 2018, 178, 715-721.	1.5	33
18	Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2022, 158, 300.	4.1	33

#	ARTICLE	IF	CITATIONS
19	Loss of Skin Microbial Diversity and Alteration of Bacterial Metabolic Function in Hidradenitis Suppurativa. <i>Journal of Investigative Dermatology</i> , 2020, 140, 716-720.	0.7	32
20	Duration of oral antibiotic therapy for the treatment of adult acne: A retrospective analysis investigating adherence to guideline recommendations and opportunities for cost-savings. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 822-827.	1.2	28
21	Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. <i>British Journal of Dermatology</i> , 2019, 181, 1339-1341.	1.5	28
22	A survey of dermatology resident education in cosmetic procedures. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, e23-e28.	1.2	23
23	Actinic Keratosis Clinical Practice Guidelines: An Appraisal of Quality. <i>Dermatology Research and Practice</i> , 2015, 2015, 1-7.	0.8	19
24	Severity and Area Score for Hidradenitis (<scp>SASH</scp>): a novel outcome measurement for hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 182, 940-948.	1.5	18
25	Hidradenitis Suppurativa Area and Severity Index Revised (HASIâ€œ): psychometric property assessment*. <i>British Journal of Dermatology</i> , 2021, 184, 905-912.	1.5	18
26	Differences Between Children and Adults With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2021, 157, 1095.	4.1	18
27	Bundled Payment Models for Actinic Keratosis Management. <i>JAMA Dermatology</i> , 2016, 152, 789.	4.1	16
28	Exploring Coping Strategies for Patients With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2016, 152, 1166.	4.1	15
29	Variation in the Cost of Managing Actinic Keratosis. <i>JAMA Dermatology</i> , 2017, 153, 264.	4.1	15
30	Positron emission tomography costs less to patients than conventional screening for malignancy in dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 140-144.	3.4	15
31	Support group utilization and impact for patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 216-219.	1.2	15
32	Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa*. <i>British Journal of Dermatology</i> , 2021, 184, 681-687.	1.5	15
33	Qualitative study shows disease damage matters to patients with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1269-1270.	1.2	13
34	Prevalence and Impact of Dietary Avoidance among Individuals with Hidradenitis Suppurativa. <i>Dermatology</i> , 2020, 236, 289-295.	2.1	12
35	Periodic worsening, or flare, in hidradenitis suppurativa: the perspective of people with hidradenitis. <i>British Journal of Dermatology</i> , 2020, 182, 218-219.	1.5	11
36	Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States. <i>JAMA Dermatology</i> , 2022, 158, 68.	4.1	11

#	ARTICLE	IF	CITATIONS
37	Trichoblastic Carcinoma Associated with Multiple Familial Trichoepithelioma. <i>Dermatologic Surgery</i> , 2012, 38, 2018-2021.	0.8	10
38	The associations of depression and coping methods on health-related quality of life for those with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1137-1139.	1.2	10
39	E-cadherin and p120ctn protein expression are lost in hidradenitis suppurativa lesions. <i>Experimental Dermatology</i> , 2019, 28, 867-871.	2.9	9
40	Development and initial validation of the <sc>HS-IGA</sc> : a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials*. <i>British Journal of Dermatology</i> , 2022, 187, 203-210.	1.5	8
41	Increased risk of alopecia areata for people with hidradenitis suppurativa in a cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1431-1432.	1.2	7
42	A narrative review of the definition of "flare" in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 182, 24-28.	1.5	6
43	Standing up together to the shame and stigma associated with hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2020, 182, 267-268.	1.5	6
44	Unraveling the Heterogeneity of Hidradenitis Suppurativa with Phenotype Schema. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1136-1138.	0.7	6
45	Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2021, 157, 379.	4.1	6
46	Hidradenitis Suppurativa Quality of Life (HiSQOL): creation and validation of the Polish language version. <i>Postępy Dermatologii i Alergologii</i> , 2021, 38, 967-972.	0.9	6
47	International consensus definition of disease flare in hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2022, 187, 785-787.	1.5	6
48	The effect of antimicrobial washes on antibacterial resistance in hidradenitis suppurativa lesions. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 821-822.	1.2	5
49	Use of thermal imaging and a dedicated wound-imaging smartphone app as an adjunct to staging hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2022, 186, 723-726.	1.5	5
50	Workplace formative assessment: faculty members' beliefs. <i>Clinical Teacher</i> , 2016, 13, 33-37.	0.8	4
51	Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1577-1581.	2.4	4
52	Psychosocial impact of hidradenitis suppurativa: a practical guide for clinicians. <i>Journal of Dermatological Treatment</i> , 2021, , 1-8.	2.2	4
53	Internalized skin bias: validation study to explore the impact of the internalization of social stigma on those with hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, , .	2.4	4
54	Cross-sectional study reveals reduced odds of allergies in people with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 232-234.	1.2	3

#	ARTICLE	IF	CITATIONS
55	Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 61-67.	1.2	3
56	Associations of Internalized Skin Bias With Age, Adverse Psychopathology, and Health-Related Quality of Life Among Patients With Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2022, 158, 432.	4.1	3
57	The use of donated products to train residents to perform injectable cosmetic procedures. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 382-385.	1.2	2
58	Information framing effects on patients' decisions about dysplastic nevus management. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1011-1013.	1.2	2
59	Efficacy of pediatric dermatology Extension for Community Healthcare Outcomes (ECHO) sessions on augmenting primary care providers' confidence and abilities. <i>Pediatric Dermatology</i> , 2021, , .	0.9	2
60	Summertime scorcher: assessing and promoting sunscreen protection in an amusement park setting. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2014, 30, 195-201.	1.5	1
61	Dermatologists and Antibioticsâ€”Reflecting on Our Habits, the Evidence, and Next Steps. <i>JAMA Dermatology</i> , 2019, 155, 286.	4.1	1
62	Response to Ring et al.: In Silico Predictive Metagenomic Analyses Highlight Key Metabolic Pathways Impacted in the Hidradenitis Suppurativa Skin Microbiome. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1476-1479.	0.7	1
63	Damage in Hidradenitis Suppurativa: A Narrative Review Emphasizing the Need for a Novel Outcome Measure. <i>British Journal of Dermatology</i> , 2022, , .	1.5	1
64	Future directions in hidradenitis suppurativa. <i>Dermatological Reviews</i> , 0, , .	0.5	1
65	Reply: Injectable products considered â€œsamplesâ€. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 198-199.	1.2	0
66	Practitioner research and formative assessment. <i>Clinical Teacher</i> , 2016, 13, 28-32.	0.8	0
67	Bundled payment for actinic keratosis management: Pilot evaluation of developed models. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 679-684.	1.2	0
68	Dose, duration, and cost: opportunities to improve use of long-term oral antibiotics for people with rosacea. <i>Journal of Dermatological Treatment</i> , 2019, 30, 63-67.	2.2	0
69	Characterizing physical symptoms of flare in hidradenitis suppurativa: a patient survey. <i>British Journal of Dermatology</i> , 2021, 184, 160-162.	1.5	0
70	Therapy of SÃ©zary syndrome. <i>Expert Review of Dermatology</i> , 2009, 4, 567-579.	0.3	0
71	Disease Evaluation and Outcome Measures. , 2022, , 121-129.		0